Overview
No overview information available.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Research Report
The Sulfate Ion (DB14546): A Comprehensive Monograph on its Physicochemical, Biological, Pharmacological, and Environmental Significance
Executive Summary
The sulfate ion (DrugBank ID: DB14546, CAS: 14808-79-8), a simple divalent anion, represents a molecule of profound and multifaceted significance. While it possesses direct pharmacological activity as a medication, specifically as an osmotic laxative, this application constitutes only a narrow facet of its overall importance. This report provides a comprehensive, multi-domain analysis of the sulfate ion, revealing its identity as a fundamental biological component, a critical tool in pharmaceutical sciences, a versatile industrial chemical, and a major environmental agent. Biologically, sulfate is the fourth most abundant anion in human plasma, essential for detoxification, metabolic regulation, and the structural integrity of tissues. Its role in the sulfonation of hormones, neurotransmitters, and xenobiotics is a cornerstone of human physiology, and its availability is critical for proper fetal development. In pharmacology, beyond its use as a laxative, sulfate's primary contribution is as a counter-ion. By forming salts with basic active pharmaceutical ingredients (APIs), it enhances their solubility, stability, and bioavailability, making many essential drugs—from antibiotics to opioids—viable for clinical use. Industrially, sulfate compounds are cornerstones of agriculture, construction, and manufacturing. Environmentally, sulfate presents a complex paradox: it is the principal agent of acid rain, causing widespread ecological damage, yet as an atmospheric aerosol, it exerts a significant cooling effect on the global climate. This report synthesizes these disparate roles, demonstrating that the function and impact of the sulfate ion are entirely defined by its chemical, biological, and environmental context. Understanding this context is essential for clinicians, scientists, and policymakers ali
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2025/07/08 | Not Applicable | Recruiting | Syed Hamza Mufarrih | ||
2025/03/19 | Phase 3 | Not yet recruiting | |||
2024/12/19 | Not Applicable | Recruiting | Arooj Khan | ||
2024/07/25 | N/A | Not yet recruiting | |||
2024/04/16 | Phase 3 | Recruiting | |||
2024/02/01 | Not Applicable | Completed | Fahad Javed Awan | ||
2023/06/28 | Phase 3 | Recruiting | |||
2022/12/01 | Phase 3 | Withdrawn | |||
2022/09/16 | Phase 2 | Active, not recruiting | |||
2022/07/20 | Phase 3 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
Healthlife of USA | 69517-133 | ORAL | 65 mg in 1 1 | 12/20/2017 | |
Uriel Pharmacy, Inc. | 48951-4197 | ORAL | 1 [hp_X] in 1 1 | 8/1/2025 | |
Carwin Pharmaceutical Associates, LLC | 15370-102 | ORAL | 9.5 mg in 1 mL | 4/21/2017 | |
Pangea Pharmaceuticals, LLC | 81279-101 | ORAL | 9.5 mg in 1 mL | 12/22/2023 | |
PD-Rx Pharmaceuticals, Inc. | 72789-436 | ORAL | 65 mg in 1 1 | 5/7/2025 | |
Method Pharmaceuticals, LLC | 58657-327 | ORAL | 10 mg in 1 mL | 12/12/2023 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
FEFOL Iron and Folic Acid Delayed Release Capsules blister pack | 12987 | Medicine | A | 8/14/1991 | |
FERROGRAD C tablet blister pack | 66843 | Medicine | A | 4/27/1999 | |
WAGNER PROFESSIONAL Ferro-Sustain Modified Release Tablets | 322181 | Medicine | A | 8/22/2019 | |
FERROSUL FOLIC MR TABS 250 mg/ 300 mcg bottle pack | 343017 | Medicine | A | 9/4/2020 | |
Pharmacy Choice IRON+C ferrous sulfate 325 mg with Ascorbic Acid 500 mg modified release tablet | 395493 | Medicine | A | 9/5/2022 | |
Beauty Collagen + Bone Support | 390521 | Medicine | A | 6/16/2022 | |
Ferro-Max C Iron & Vitamin C modified release tablets | 322081 | Medicine | A | 8/21/2019 | |
Aone Iron + C modified release tablets | 413668 | Medicine | A | 7/18/2023 | |
Hydralyte Sports Orange Flavoured Effervescent Electrolyte Tablets | 346493 | Medicine | A | 10/23/2020 | |
Hydralyte Sports Lemon Lime Flavoured Electrolyte Ice Blocks | 343445 | Medicine | A | 9/14/2020 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
FERINSOL DROPS | mead johnson nutritionals | 00017841 | Drops - Oral | 125 MG / ML | 12/31/1951 |
FERROUS SULFATE TABLETS 300MG | pharmadex laboratories inc. | 01987135 | Tablet - Oral | 300 MG | 12/31/1993 |
LIVRON PLUS AMPOULE | medic laboratory ltée | 00520004 | Liquid - Oral | 36 MG / 10 ML | 12/31/1980 |
ARCHANGELICA COMP. PELLETS | 02232700 | Pellet - Oral | 2 D | 4/10/1998 | |
PILULES DUCASE | produits francais labs inc. | 00166359 | Tablet - Oral | 5 MG | 12/31/1930 |
NOVO-FERROSULFA TAB 300MG(FCT) | novopharm limited | 00021962 | Tablet - Oral | 300 MG | 12/31/1991 |
FERROUS SULFATE ECT 300MG | bionatal drug co | 00332747 | Tablet (Enteric-Coated) - Oral | 300 MG | 12/31/1977 |
FERRUM SULFURICUM-INJEEL LIQ (10D,30D,200D/1.1ML) | 02063107 | Liquid - Oral | 10 D / 1.1 ML | 12/31/1994 | |
HOMEOPATHIC MEDICINE (S#755) DPS 30C | total health centre | 02081121 | Drops - Oral | 30 C / ML | 12/31/1994 |
FERROUS SULFATE TAB 325MG USP | 00722413 | Tablet - Oral | 325 MG | 12/31/1991 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
No CIMA AEMPS (Spain) approvals found for this drug. |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.